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Introduction
From 1996 onward, the advent of antiproteases and the introduction 
of Highly Active Antiretroviral Therapies (HAART) have enabled 
considerable progress in survival [1]. To achieve these aims, the success 
of first-line HAART has been shown to be of particular importance. 
Subsequent treatment regimens were less likely to be successful after 
a first-line HAART discontinuation [2]. Patients interrupting first-
line HAART within two months after treatment initiation had poorer 
clinical results than those who had not stopped [3]. Discontinuation 
due to intolerance could reduce compliance with later regimens, 
and interruptions due to failure (clinical and/or immunological and 
virological) may raise the risk of development of resistant viral strains 
[4]. In clinical practice, premature discontinuations are frequent, 
ranging from 36% to 61% at 12 months [5-10]. Discontinuation due 
to intolerance has been reported to be the main cause in most cohorts, 
followed by discontinuation due to failure or to problems of compliance. 
The risk factors for discontinuation found in the literature can be 
grouped into three categories: (1) patient-related factors: age, sex, race, 
educational level, mode of HIV acquisition; (2) disease-related factors: 
CD4, plasma viral load (VL) at baseline or at discontinuation, AIDS 
stage; and (3) treatment-related factors: once or twice daily, pill burden, 
type of treatment.
These results were generally yielded by two main models (Logistic 
models or Poisson models) and in the vast majority of studies, the 
estimator of the cumulative incidence, the complement 1-KM [11] 
of Kaplan-Meier and Cox model [12] for risks factors were applied. 
This “standard” approach makes the assumption of non-informative 
censoring. Concerning first-line HAART discontinuations, this means 
that the occurrence, for example, of a discontinuation for intolerance 
does not affect the risk of observing another type of discontinuation 
(treatment failure, treatment simplification or other reasons). This 
assumption is questionable in a context of multiple events of interest 
such as first line HAART discontinuation. Indeed, the different 
types of discontinuations are in competition insofar as a patient who 
discontinued for any reason can no longer stop the treatment for 
another reason. By considering other events than the event of interest 
as censored observations, the standard approach could overestimate 
the incidence of the event of interest and bias the estimated effects 
of potential risk factor of discontinuation [11,13]. In the presence of 
competing risks, an alternative analysis of the cumulative incidence is 
based on the CIF estimator (Cumulative Incidence Function) [14] and 
Fine-Gray model for identifying the risk factors [15]. This “competing 
risk approach” considers the nature of informative censoring due to 
competing event, which is defined as an event whose occurrence alters 
the risk of occurrence of a main event under examination. Although 
competing risks may refer to events that are mutually non-exclusive 
[16], most calculation strategies are adapted to a follow-up which ends 
at the first event, thus (artificially) creating a competitive situation. 
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Objectives: To estimate the incidences of first-line HAART discontinuation (for intolerance, treatment failure or 
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Methods: We studied 1136 patients receiving first-line Highly Active Antiretroviral Therapies (HAART), aged 
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rare events, potentially exposed to competing risk, results differed. The common or specific nature of a factor may 
also play a role.
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Our aim in this cohort study was thus, to compare results obtained 
with the standard approach (1-KM, Cox model) and the competing risk 
approach (CIF, Fine-Gray model) in the estimation of the incidence of 
first-line HAART discontinuation (for intolerance, treatment failure or 
treatment simplification) and their risk factors in HIV infected patients.
Methods
Originally called NADIS, Dat’AIDS is a multicenter cohort based 
on a computerized medical record that is used by clinicians in real time 
during their consultations. Overall follow-up is every three months, 
and the cohort was set up from 2000 onwards in six French teaching 
hospitals, including the Toulouse Teaching Hospital. The national 
Dat’AIDS database covers more than 10% of patients treated in French 
hospitals. Patients give their prior written informed consent to use their 
anonymous data for research and evaluation purposes. This tool has 
been described in detail by elsewhere [17].
Study population
The study population consisted of all HIV-positive patients who 
started first-line antiretroviral therapy (HAART) between January 
1, 2000 and June 30, 2008 in the department of infectious and 
tropical diseases of Toulouse teaching hospital. Only HIV-1 positive, 
antiretroviral-naive patients older than 18 years were included in the 
study. Patients included in clinical trials or those with undetectable 
viral load at treatment initiation were excluded.
Prognosis variables and data collection 
Disease-related variables were: mode of HIV acquisition, inclusion 
in a therapeutic education program during the three months before 
HAART initiation or within two weeks afterwards, AIDS-defining 
illness at treatment initiation, date of first HIV positive diagnosis, 
year of treatment initiation in four classes ([2000–2001], [2002–2003], 
[2004–2005] and [2006–2008]), type of first-line regimen coded as 
follows : two nucleoside reverse transcriptase inhibitors (2NRTI) with 
a boosted protease inhibitor or not (1PI/1PIb); two nucleoside reverse 
transcriptase inhibitors (2NRTI) with one non-nucleoside reverse 
transcriptase inhibitor (1NNRTI); and other alternative combinations 
(one or two drugs, other three drugs combinations, or four drugs). 
CD4 measurements and viral load (VL) were collected at treatment 
initiation, within a maximum of three months for CD4 levels and 
one month for VL. The peripheral blood CD4 lymphocyte count was 
obtained by flow cytometry (Epics Profile, Coulter, Hialeah, Florida, 
USA). It was expressed as the number of cells per mm3 and divided 
into three categories: <200 cells/mm3 (reference), (200–350) and ≥ 
350. VL was measured using the Amplicor HIV-1 Monitor technique 
(Laboratoire Roche-Diagnostic, Meylan, France). It was expressed 
in log10-copies/ml and divided into three categories: ([1.7-4.0] [log10 
copies/ml] (reference), [4.0-5.0]) and ≥ 5.0. All these data were collected 
at or around treatment initiation.
Events of interest and data collection
A discontinuation was defined as a change or a cessation of one or 
more drugs of the initial regimen, as recorded by the physician. Th e 
date on which it occurred was recorded. Dose modifications were not 
accounted for. Four events of interest were considered: (1) the intolerance, 
defined as an adverse effect after taking at least one HAART drug and 
leading to discontinuation or change of the treatment regimen. (2) The 
treatment failure: clinical onset of symptoms of disease progression; 
absence of increase in CD4 count in spite of antiretroviral treatment, 
non-optimal decrease in VL at 6 months or occurrence of an increase 
in a previously undetectable VL.  (3) The treatment simplification: a 
change in treatment intended to facilitate intake by the patient (once a 
day instead of twice, fewer pills at each time) and (4) the “other causes”: 
mostly unknown or related to patient wish, problems of compliance, 
breast-feeding or pregnancy. When several events of interest were 
observed simultaneously in a given patient, data collection focused on 
the clinical event that the physician considered most relevant.
 Statistical analysis
The first step concerned the estimation of incidence. Our survival 
analysis was based on estimation of the cumulative incidence for one of 
the multiple events of interest, in the presence of competing risks. Death 
was not a cause of censoring, as no death occurred during follow-up. We 
first used the non-parametric Kaplan-Meier method that estimates usually 
the overall survival probability of an event of interest, noted by KM. The 
cumulative incidence was deduced from the complement 1-KM [11] of 
this probability, which is the probability of having the event of interest at 
a given time. In this standard approach, the observed events other than 
this of interest are considered as non-informative censoring. Then, we 
estimated the cumulative incidence in the context of competing risks 
by CIF estimator, proposed by Kalbflesih and Prentice in 1980 [14]. CIF 
estimator became available on STATA in 2004 [18].
In a second step, risk factors were analyzed. Two approaches were 
used: the Cox model [12] and the Fine-Gray regression model [15]. Cox 
model is based on the cause-specific hazard function and takes into 
account patients who had the event of interest, the other patients being 
treated as censored. The method proposed by Fine and Gray, models the 
subdistribution hazard function to take into account competing risks, 
by introducing the probability of having a competing event before the 
event of interest. It gives the possibility to express effects of covariates 
directly on the cumulative incidence function.
For each event of interest, the variables identified in the literature 
as being associated with discontinuation of first-line treatment (sex, 
mode of HIV acquisition, type of treatment, age, and immunological 
and virological measurements at baseline) as well as variables that were 
significant at a p<0.20 level in bivariate analysis were included in each 
of Cox and Fine-Gray regressions models. Significance was assessed by 
using the overall p-value of all the indicators of each variable, using 
the Wald test for Cox and Fine-Gray models. In order to compare the 
results of the two models for each event of interest, we run models on 
the same population by excluding patients who had at least one missing 
item for one of the studied risk factors. A manual stepwise descending 
strategy, adapted from the method of Hosmer and Lemeshow was used 
to eliminate successively the factors with p>0.05. We then tested the 
interactions which were of clinical significance. To obtain the final 
model, we compared the model without interaction containing the 
variables with p<0.05, with the model with interaction using the Akaike 
Information Criterion (AIC). Risks proportionality assumption was 
checked by using, for the Cox model, the test proposed by Grambsch 
and Thernaud [19], and for the Fine-Gray model by testing the 
interaction between each variable and the logarithm of time. Lastly, 
we tested the robustness and goodness of fit of the model using Cox-
Snell residuals for the Cox model and standardized score residuals for 
the Fine-Gray model. All analyses were carried out with STATA V11.2 
software (Statacorp, College Station, TX).
Results
Population
Mean age (± standard deviation) at treatment initiation was 40 years 
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(± 10 years) and 67.8% (N=770) were men. The most frequent mode of 
acquisition was heterosexual (48.6%, N=552), with homosexual and/or 
bisexual acquisition accounting for 34.2% (N=389) of infections. Nearly 
71.2% (N=808) of patients started first-line HAART between 2000 and 
2005 and one-fifth of patients had undergone a treatment education 
program. The first-line regimens consisted of 2NRTI +1PI/1PIb for 
35.7% (N=406) of patients, 33.5% (N=380) received 2NRTI +1NNRTI, 
and 30.8% (N=350) received other treatment regimens. Half of the 
patients started treatment nearly two years after the diagnosis, and 
13.3% (N=151) had AIDS-defining illnesses. CD4 counts ranged 
between 0 and 1341 cells/mm3. VL ranged between 1.7 to 7.0 log10 
copies/mm3. These data are summarized in table 1.
Causes of discontinuation of first-line treatment
As a whole, 776 of the 1136 patients discontinued first line 
regimen, including 265 for intolerance, 101 for treatment failure, 136 
for treatment simplification, and 274 for other reasons. The estimated 
incidence was 34 (95% Confidence Interval, CI, [32–37]) per 1000 
person-months. The cumulative incidence of discontinuation for all 
causes was 30.3% (27.6–31.6) at six months, 44.3% (41.3–47.3) at one 
year, 58.5% (55.4–61.6) at two years, 76.5% (73.5–79.5) at four years and 
89.4% (85.5–92.6) at eight years. Median time to discontinuation, for 
any cause, was 15.3 months (InterQuartile Range, IQR, 4–45 months).
Cumulative incidence of discontinuation according to 
the 1-KM (Standard survival) and CIF (competing risk) 
estimators
With the 1–KM estimator, the median time to discontinuation for 
intolerance was 93.8 months. Median was not reached for treatment 
simplification or for treatment failure. With the CIF estimator, no cause 
reached the median. Figures 1 and 2 show the cumulative incidences 
estimated according to both approaches and using the CIF estimator 
respectively.
Whatever the approach used, the proportion of discontinuation 
because of intolerance was always greater than the proportions of the 
other causes of discontinuation. Using competing risk and standard 
Baseline characteristics Total (n = 1136)
Men/Women, n (%) 770 (67.8)/366 (32.2)
Age at HAART initiation (years)
Mean (standard deviation) 40 (10.4)
[18–50[, n (%) 963 (84.8)
[50–82], n (%) 173 (15.2)
Mode of HIV acquisition, n (%)
Heterosexual 552 (48.6)
Homosexual/Bisexual 389 (34.2)
Injection drug use 84  (7.4)
Other/Unknown 111 (9.8)





Therapeutic education, Yes, n (%) 226 (19.9) 




Other regimens 350 (30.8)
Death, Yes, n (%)     0   (0.0)
AIDS-defining illness at HAART initiation, n (%)
Yes 151 (13.3)
Missing data   44  (3.9)
Duration HIV seropositivity (years)
Mean (standard deviation) 4.7 (5.7)
CD4 cell count at HAART initiation (cells/mm3)
Mean (standard deviation) 264.9 (196.6)
Missing data, n (%)  210 (18.5)
Viral load at HAART initiation (log10 copies/mm3)
Mean (standard deviation)  4.6 (1.1)
Missing data, n (%) 307(27.0)
‡ PIb = boosted protease inhibitor
Table 1: Characteristics at treatment initiation of the 1136 participants receiving 
first-line HAART between January 1, 2000 and June 30, 2008 among patients 
treated at Toulouse Teaching Hospital.
Figure 1: KM versus CIF, Cumulative incidence for types of first line HAART discontinuations in 1136 HIV infected patients
Cumulative incidences according to 1-KM (standard survival) and CIF (competing risk approach) for first-line HAART discontinuations due to intolerance, treatment 
failure, treatment simplification and other causes. For each of the four events, 1-KM over estimates cumulative incidence. The differences between the two approaches 
were larger as the duration of follow-up increased.
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survival analysis, the estimations at one year were respectively 16.8% 
and 19.0% for intolerance, 4.5% and 6.3% for treatment failure, 5.7% 
and 8.0% for treatment simplification and, 17.3% versus (vs) 20.0% for 
other causes. The sum of specifics probabilities estimated by standard 
survival analysis was higher than the overall cumulative incidence (at 
one year, 53.3% vs 44.3%), which is not the case by using competing 
risk approach.
Analysis of factors associated with discontinuation of first-
line treatment according to the Cox (Standard survival) and 
Fine-Gray (competing risk) Models 
 Multivariate analyses were applied for each model on the 
same population of 793 patients who had no missing data for all risk 
factors studied. For each cause of discontinuation, the interactions 
tested in the Cox or Fine-Gray model were not significant.
Risk factors of discontinuation of first-line treatment due to 
intolerance
Among the 793 patients, 191 discontinued treatment due to 
intolerance. The remaining 602 were considered as conventional 
right censoring by the Cox model and classified as 348 censorings of 
concurrent events and 254 conventional right censorings by the Fine-
Gray model. Similar risk factors were identified by both models (Table 
2). Participation in a therapeutic education program, age over 50 years 
and high viral load were the three factors associated with a higher risk 
of discontinuation for intolerance in the two adjusted models. The Cox 
model also detected a trend towards significance of AIDS-defining 
illness (p=0.0562), that was not identified as a risk factor by using 
competing risk approach.
Risk factors of discontinuation of first-line treatment because 
of treatment failure
Among the 793 patients included, 64 discontinuations for treatment 
failure were observed. The 729 remaining cases were considered as 
conventional right censoring by the Cox model and classified as 475 
censorings concurrent events and 254 conventional right censorings 
according to the Fine-Gray model. The type of first-line treatment and 
the duration of HIV infection were similarly identified as risk factors 
in both the Cox model and Fine-Gray model. AIDS-defining illness 
at treatment initiation increased the probability of discontinuation 
for treatment failure with the Cox model, but not with the Fine-Gray 
model (Table 3). 
Risk factors of discontinuation of first-line treatment for 
treatment simplification
Discontinuation for treatment simplification occurred in 107 
of the 793 patients. The 686 remaining patients were considered as 
conventional right-censored data with the Cox model and classified 
as 432 censorings of concurrent events and 254 conventional right 
censorings with the Fine-Gray model. Risk factors are shown in table 4. 
Mode of HIV acquisition and year of treatment initiation were identified 
as risk factors in both the Cox model and in the Fine-Gray model. In 
the Cox model but not in the Fine-Gray model, patients receiving a 
regimen combining 2NRTI+1NNRTI tended to have a lower risk of 
discontinuation for simplification than patients who had received 
2NRTI+1PI/1PIb. In the Cox model, the probability of discontinuation 
for treatment simplification was greater for patients with VL >5 log10 
copies/mm3 than for those with VL between (1.7-4) log10 copies/mm3 
Figure 2: All reasons of first-line HAART discontinuations and the CIF 
estimation for types of discontinuations in 1136 HIV infected patients
Cumulative incidences of all reasons and the CIF estimation for types of first-
line HAART discontinuations. The sum of specifics probabilities estimates 
by standard survival analysis (see also figure 1) was higher than the overall 
cumulative incidence which is not the case by using competing risk approach. 
By example, one year cumulative incidences were 53.3% versus 44.3%. 
Theses analysis also showed over estimation of 1-KM.
Bivariate analysis Multivariate analysis, n =793
Occurrence Cox Fine-Gray Cox Fine-Gray
Characteristics n =1136 % HR$crude[80% CI] P SHR
¶
crude[80% CI] P HRajusted[95% CI] P * SHRajusted[95% CI] P *
Age at Ti **(year) 0.0048 0.0013 0.0264 0.0058
[18 – 50] 210 21.81 1(Reference) 1(Reference) 1(Reference) 1(Reference)
[50 – 82]   55 31.79 1.53 [1.26–1.86] 1.61 [1.33–1.95] 1.47 [1.04–2.07] 1.60 [1.14–2.25]
Therapeutic education <0.0001 <0.0001 0.0241 0.0341
No 202 22.20 1(Reference) 1(Reference) 1(Reference) 1(Reference)
Yes   63 27.88 1.77 [1.47–2.14] 1.57 [1.30–1.90] 1.43 [1.04–1.97] 1.39 [1.02–1.89]
AIDS-defining illness N=1092 100% 0.0006 0.0129 0.0511 0.1605
No 209 22.21 1(Reference) 1(Reference) 1(Reference) 1(Reference)
Yes   47 31.13 1.74 [1.41–2.14] 1.50 [1.21–1.86] 1.45 [0.99–2.10] 1.31 [0.89–1.92]
VL (log10 copie/mm3) Ti ** N=829 100% 0.0216 0.0173 0.0392 0.0308
[1.7– 4.0]   32 16.75 1(Reference) 1(Reference) 1(Reference) 1(Reference)
[4.0– 5.0]   86 26.71 1.74 [1.33–2.27] 1.75 [1.35–2.28] 1.71 [1.12–2.60] 1.73 [1.15–2.60]
≥ 5.0   79 25.00 1.66 [1.26–2.17] 1.66 [1.27–2.17] 1.41 [0.91–2.18] 1.48 [0.97–2.26]
* P-value obtained by backward stepwise regression
** Ti : Time of HAART initiation
$ Hazard Ratio obtained by Cox model
¶ Subdistribution Hazards Ratio obtained by Fine-Gray model
Table 2: Baseline risk factors of first line HAART discontinuation for intolerance: Cox and Fine-Gray models.
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(Hazard Ratio, HR=1.90, 95% CI 1.08-3.34). This difference was not 
strictly significant in the Fine-Gray model even though the relative 
risks did not greatly differ.
Discussion
Whatever the approaches used, (1-KM) or CIF, our results show 
that without “other causes”, the incidence of discontinuation was 
in decreasing order of importance due to, intolerance, treatment 
simplification, and treatment failure. As expected, cumulative incidence 
was overestimated in standard survival (1-KM) compared with the CIF 
estimator of the competing risk approach. In contrast, regarding risk 
factors, our analyses showed that the identified risk factors could differ 
according to the statistical model (Cox or Fine-Gray) and the cause 
of discontinuation. Risk factors differed according to the statistical 
approach used, as observed for treatment failure and treatment 
Bivariate analysis Multivariate analysis, n = 793
Occurrence Cox Fine-Gray Cox Fine-Gray
Characteristics n = 1136 % HR$crude[80% CI] P SHR
¶
crude[80% CI] P HRajusted[95% CI] P* SHRajusted[95% CI] P*
Year of first HAART 0.1448 0.0043 0.3461 0.0191
[2000–2001] 43 13.74 1(Reference) 1(Reference) 1(Reference) 1(Reference)
[2002–2003] 32 13.22 1.18 [0.87–1.59] 1.02 [0.76–1.38] 1.09 [0.59–1.98] 0.97 [0.55–1.73]
[2004– 2005] 16   6.32 0.72 [0.49–1.06] 0.50 [0.34–0.73] 0.53 [0.23–1.21] 0.36 [0.16–0.78]
[2006– 2008] 10   3.05 0.55 [0.34–0.87] 0.38 [0.24–0.59] 0.68 [0.27–1.72] 0.43 [0.17–1.06]
First HAART regimen 0.0001 0.0001 0.0060 0.0444
2NRTI + 1PI/1PIb
‡ 19   4.68 1(Reference) 1(Reference) 1(Reference) 1(Reference)
2NRTI + 1NNRTI 28   7.37 1.20 [0.82–1.77] 1.53 [1.04–2.24] 1.70 [0.79–3.67] 1.82 [0.84–3.94]
 Other regimens 54 15.43 2.66 [1.88–3.75] 2.86 [2.03–4.02] 2.94 [1.47–5.88] 2.38 [1.20–4.71]
HIV seropositivity duration (years) 0.0032 0.0011 0.0094 0.0039
<0.169 28   9.89 1(Reference) 1(Reference) 1(Reference) 1(Reference)
[0.16– 1.83] 13   4.56 0.45 [0.29–0.69] 0.49 [0.32–0.76] 0.64 [0.29–1.39] 0.68 [0.30–1.52]
[1.83– 8.27] 18   6.34 0.56 [0.38–0.82] 0.65 [0.44–0.95] 0.80 [0.35–1.83] 0.68 [0.30–1.53]
[8.27– 24.02] 42 14.79 1.19 [0.87–1.63] 1.45 [1.06–1.99] 1.92 [1.04–3.54] 1.94 [1.05–3.58]
AIDS-defining illness n=1092 100% 0.0059 0.1239 0.0311 0.1201
No 76   8.08 1(Ref) 1(Ref) 1(Ref) 1(Ref)
Yes 18 11.92 2.06 [1.47–2.88] 1.50 [1.07–2.11] 2.05 [1.06–3.95] 1.74 [0.86–3.50]
* P-value obtained by backward stepwise regression
** Ti =Time of HAART initiation
‡ PIb = boosted protease inhibitor
$ Hazard Ratio obtained by Cox model
¶ Subdistribution Hazards Ratio obtained by Fine-Gray model
Table 3: Baseline risk factors of first line HAART discontinuation for treatment failure: Cox and Fine-Gray models.
Bivariate analysis Multivariate analysis, n = 793
Occurrence Cox Fine-Gray Cox Fine-Gray
Characteristics n = 1136 % HR$crude[80% CI] P SHR
¶
crude[80% CI] P HRajusted[95% CI] P* SHRajusted[95% CI] P*
Mode of HIV acquisition 0.0255 0.0373 0.0290 0.0119
Heterosexual 67 12.14 1(Reference) 1(Reference) 1(Reference) 1(Reference)
Homosexual /Bisexual 57 14.65 1.18 [0.94–1.49] 1.22 [0.97–1.53] 1.45 [0.97–2.16] 1.62 [1.09–2.41]
Injection drug use  6  7.14 0.51 [0.29–0.88] 0.52 [0.30–0.90] 0.99 [0.38–2.52] 0.77 [0.30–1.94]
Other/Unknown  6  5.41 0.40 [0.23–0.70] 0.45 [0.26–0.78] 0.30 [0.09–0.97] 0.39 [0.12–1.28]
Year of first HAART <0.0001 <0.0001 <0.0001 <0.0001
[2000–2001[ 30  9.58 1(Reference) 1(Reference) 1(Reference) 1(Reference)
[2002– 2003[ 32 13.22 1.78 [1.28–2.48] 1.52 [1.10–2.10] 1.44 [0.80–2.59] 1.32 [0.75–2.31]
[2004– 2005[ 60 23.72 4.48 [3.30–6.08] 3.15 [2.38–4.17] 3.02 [1.72–5.29] 2.54 [1.56–4.13]
[2006– 2008] 14  4.27 1.37 [0.88–2.13] 0.83 [0.55–1.25] 0.90 [0.41–1.96] 0.65 [0.32–1.32]
First HAART regimen 0.0151 0.1588 0.0548 0.4172
2NRTI + 1PI/1PIb 
‡ 52 12.81 1(Reference) 1(Reference) 1(Reference) 1(Reference)
2NRTI + 1NNRTI 35  9.21 0.53 [0.40–0.70] 0.66 [0.50–0.87] 0.56 [0.34–0.91] 0.73 [0.46–1.16]
Other 49 14.00 0.85 [0.66–1.11] 0.89 [0.69–1.15] 0.89 [0.55–1.44] 0.89 [0.55–1.43]
VL at Ti (log10 copies/mm3) N= 829 100% 0.0018 0.0046 0.0266 0.0537
[1.7 – 4.0] 20 10.47 1(Reference) 1(Reference) 1(Reference) 1(Reference)
[4.0–5.0] 35 10.87 1.23 [0.85–1.76] 1.09 [0.76–1.56] 1.18 [0.65–2.13] 1.07 [0.60–1.90]
≥ 5.0 57 18.04 2.21 [1.58–3.09] 1.95 [1.40–2.71] 1.90 [1.08–3.34] 1.69 [0.98–2.89]
* P-value obtained by backward stepwise regression
** Ti : Time of HAART initiation
‡ PIb = boosted protease inhibitor
$ Hazard Ratio obtained by Cox model
¶ Subdistribution Hazards Ratio obtained by Fine-Gray model
Table 4: Baseline risk factors of first line HAART discontinuation for treatment simplification: Cox and Fine-Gray models
Citation: Keita M, Chouquet C, Cuzin L, Cissé M, Lang T, et al. (2012) Incidence and Risk Factors of First-Line HAART Discontinuation: Is it Worth 
Choosing Competing Risk or Standard Survival Approaches? J AIDS Clinic Res 3:187. doi:10.4172/2155-6113.1000187
Page 6 of 7
Volume 3 • Issue 10 • 1000187
J AIDS Clinic Res
ISSN:2155-6113 JAR an open access journal 
simplification. It was not the case for intolerance, where the same risk 
factors were identified by the Cox and Fine-Gray models.
Our study was limited to the population of one French center. 
However, the study has the merit of collecting data in real time of 
information, with a reasonably large sample and a prospective follow-
up of eight years and a half, sufficient to achieve our objectives. Due to 
close monitoring during follow-up, few patients were lost to study.
With regard to estimated incidences, in our data, the differences 
between the two approaches were larger as the duration of follow-up 
increased. These differences could be explained by the way the “risk 
set” is calculated. The 1-KM complement considers that the population 
followed is exposed only to the risk of the event of interest, like in a 
context of independent concurrent events. Like subjects lost to follow-
up, a subject who has undergone a concurrent event is no longer 
counted in the risk set. Conversely, by using the CIF approach, patients 
who have a competing event are considered in the calculation of overall 
survival, needed to estimate the cumulative incidence [20].
Regarding risk factors, our data showed that results are mixed 
according to the standard and competing risk approaches. They were 
the same for intolerance discontinuation but different regarding 
treatment failure and simplification. The time of occurrence and the 
frequency of an event of interest might explain these results. Intolerance 
is in fact frequent and occurred earlier, whereas treatment failure and 
simplification are less frequent, occurred later and thus are more 
exposed to competing risks. Wolbers et al. [21] indicated that when 
concurrent events are rare, the Cox model is equally appropriate as 
the competing risk model, which is what we found for discontinuation 
due to intolerance because it was not too much exposed to competing 
events. Conversely, discontinuations for simplification or failure 
were much more exposed to competing risk (discontinuation for 
intolerance) and consequently Cox model and Fine-Gray models gave 
different results. The “common” or “specific” nature of a given risk 
factor could also explain in part the difference observed between the 
two approaches. The Cox model would be more able to detect a risk 
factor common to different events and the Fine-Gray model would 
be more able to detect risk factors specific to a given event of interest. 
As an example, when considering discontinuations for intolerance or 
failure, in contrast with the Fine-Gray model, the Cox model identified 
AIDS-defining illness as a risk factor. One reason could be that this risk 
factor is a common cause of discontinuation, which is not specific to a 
type of discontinuation.
In conclusion, according to these results, recommendations have 
to make a clear distinction between estimation of incidence and 
identification of risk factors. As expected, 1-KM estimator overestimates 
the incidence of first-line HAART discontinuation, suggesting that 
the CIF estimator should be used in a situation where competing 
events are involved. With regard to identifying risk factors, use of 
the Cox model or the Fine-Gray model appears much more complex 
according to the research question. For early and frequent events, such 
as discontinuation due to intolerance in our example, the two models 
yielded similar results. Conversely, for later and rarer causes, more 
exposed to competing risk, the two models produced different results. 
The common or specific nature of a given factor might also play a role. 
To our knowledge, it is difficult to decide how these two models should 
be used in a context of multiple events, as shown in our example of 
treatment discontinuation. Further work is needed in order to clarify 
this question, probably through testing on simulated datasets. It should 
be emphasized that both models do not explore the same research 
question.
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